Table 1 Mean volumetric values before (mean 1), three months (mean 3) and twelve months after initiation of anti-VEGF therapy.
ERM | IRF | SRF | SRHM | RPE | fvped | drusen | PHM | Choroid | Fibrosis | CRT | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Mean 1 | 0·01 | 0·03 | 0·08 | 0·02 | 0·19 | 0·12 | 0·01 | 0·02 | 0·93 | 0·02 | 223·82 |
Mean 3 | 0·01 | 0·01 | 0·01 | 0·01 | 0·19 | 0·09 | 0·01 | 0·02 | 0·96 | 0·02 | 169·65 |
Mean 12 | 0·01 | 0·01 | 0·01 | 0·00 | 0·18 | 0·09 | 0·01 | 0·02 | 0·95 | 0·03 | 172·62 |
sd 1 | 0·02 | 0·08 | 0·25 | 0·05 | 0·02 | 0·18 | 0·01 | 0·03 | 0·41 | 0·06 | 88.29 |
sd 3 | 0·02 | 0·07 | 0·09 | 0·02 | 0·02 | 0·15 | 0·01 | 0·03 | 0·41 | 0·06 | 64·11 |
sd 12 | 0·02 | 0·04 | 0·04 | 0·01 | 0·02 | 0·15 | 0·01 | 0·03 | 0·41 | 0·08 | 63·76 |
p-value (1–3) | 0·62 | 0·00* | 0·00* | 0·00* | 0·00* | 0·02 | 0·44 | 0·39 | 0·33 | 0·59 | 0·00* |
p-value (1–12) | 0·38 | 0·00* | 0·00* | 0·00* | 0·00* | 0·05 | 0·82 | 0·24 | 0·50 | 0·15 | 0·00* |
p-value (3–12) | 0·70 | 0·94 | 0·86 | 0·32 | 0·01 | 0·59 | 0·30 | 0·74 | 0·76 | 0·05 | 0·52 |
